Skip to main content

Table 3 Univariate analysis of disease free survival among patients with baseline BMI ≥ 23 kg/m2 (N = 338)

From: Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients

   Unadjusted HR (95 % CI) p-value
Sex Male 1.46 (0.82–2.63) 0.20
Female 1  
Age ≥ 65 years 1.09 (0.62–1.90) 0.77
< 65 years 1  
Body weight change Gain ≥ 5 kg 2.01 (1.01–3.99) 0.047
Others 1  
Location Proximal 0.85 (0.48–1.50) 0.57
Distal 1  
Stage III 1.32 (0.53–3.31) 0.55
II 1  
T stage T 4 2.53 (1.36–4.72) 0.004
T 1–3 1  
N stage N 2 2.96 (1.74–5.05) <0.001
N 0–1 1  
Angiolymphatic invasion Present 3.87 (2.11–7.12) <0.001
Absent 1  
Venous invasion Present 2.50 (1.26–4.98) 0.009
Absent 1  
Perineural invasion Present 3.53 (2.05–6.07) <0.001
Absent 1  
Histology MAC 1.35 (0.42–4.34) 0.61
Non-MAC 1  
Microsatellite status MSI-H 0.70 (0.17–2.87) 0.62
MSS/MSI-L 1  
  1. Abbreviations: HR hazard ratio, CI confidence interval, MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high